Latanoprost Stulln Sine 50 Mikrogramm/Ml Augentropfen, Lösung Im Einzeldosisbehältnis (Latanoprost)

Latanoprost is a prostaglandin F2α (FP) receptor agonist. Binding to FP receptors in the ciliary body remodels the extracellular matrix, which increases uveoscleral outflow of aqueous humor. The enhanced outflow reduces intra‑ocular pressure, providing therapeutic benefit in glaucoma and ocular hypertension.

The dosing regimen for Latanoprost is determined by the prescribing clinician. Typically, one drop is instilled into the affected eye(s) once daily in the evening, but the exact dose and timing should follow the individual prescriber’s instructions.

Safety data for Latanoprost in pregnancy and lactation are limited. It is classified as a pregnancy category with unknown risk, and breastfeeding safety has not been established. Use only if the potential benefit justifies the potential risk to the fetus or infant.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Latanoprost belongs to the prostaglandin analog class, which generally provides greater 24‑hour pressure reduction and once‑daily dosing compared with beta‑blockers like timolol. Timolol works by decreasing aqueous humor production, whereas Latanoprost enhances uveoscleral outflow. Choice of therapy depends on patient tolerance, comorbidities and physician preference.

Store Latanoprost eye drops at room temperature, below 25 °C, in the original packaging. Protect the container from light and moisture, and keep the single‑dose vial tightly sealed until use to maintain sterility and potency.

Latanoprost is applied as a single drop into the conjunctival sac of the affected eye(s) once daily, preferably in the evening. The patient should wash hands before use, avoid touching the tip of the container to the eye or any surface, and close the eye gently after instillation.

Serious adverse events, although rare, include persistent ocular inflammation such as uveitis or iritis, corneal edema, and severe allergic reactions that may present with swelling, itching or rash. Any sudden vision changes or eye pain should prompt immediate medical evaluation.

Latanoprost should be avoided in patients with known hypersensitivity to the drug or any of its excipients. It is also contraindicated in individuals with active ocular inflammation, recent ocular surgery, or those in whom prostaglandin analogs are deemed unsuitable by the treating ophthalmologist.